Reviva Pharmaceuticals Holdings, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Reviva Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $8.39M.
- Reviva Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $1.04M.
- Reviva Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $1.49M.
- Reviva Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was -$1.00.
- Reviva Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for fiscal 2024 was $10.92M, a 60.28% decline from fiscal 2023.
- Reviva Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for fiscal 2023 was $27.49M, a 253.69% increase from fiscal 2022.
- Reviva Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for fiscal 2022 was $7.77M, a 75.32% decline from fiscal 2021.
- Reviva Pharmaceuticals Holdings, Inc. stock issued during period, value, new issues for fiscal 2021 was $31.50M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $8.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-03 | $10.92M 10-K · filed 2025-04-03 |
| 2024-09-30 | $1.04M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $1.49M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$1.00 derived: 10-K 12 month − 3 quarters · filed 2025-04-03 | |
| 2023-12-31 | $27.49M 10-K · filed 2025-04-03 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $7.77M 10-K · filed 2024-04-15 |
| 2022-09-30 | $7.77M 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $31.50M 10-K · filed 2023-03-30 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | |
| 2021-06-30 | $31.50M 10-Q · filed 2022-08-15 | |
| 2018-08-31 | $25.00K 10-Q · filed 2020-01-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |